Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 May;21(5):693–697. doi: 10.1128/aac.21.5.693

Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy.

C E van Rensburg, E M Gatner, F M Imkamp, R Anderson
PMCID: PMC181995  PMID: 7049077

Abstract

The effects of clofazimine on neutrophil activities such as random motility, migration to the leukoattractants endotoxin-activated serum and N-formyl-L-methionyl-L-leucyl-L-phenylalanine phagocytosis of Candida albicans, postphagocytic hexose-monophosphate shunt activity, and myeloperoxidase-mediated iodination and the effects of clofazimine on lymphocyte transformation to mitogens were assessed in vitro and after ingestion of the drug by normal individuals and patients with lepromatous leprosy. For in vitro studies, the concentration range of the drug investigated was 10(-6) M to 10(-2) M. for in vivo studies, subjects ingested 200 mg of clofazimine daily for a period of 5 days. At concentrations of 5 X 10(-6) M to 5 X 10(-3) M clofazimine caused a progressive dose-dependent inhibition of neutrophil motility without detectable effects on phagocytosis, postphagocytic hexose-monophosphate shunt activity, or myeloperoxidase-mediated iodination. Over the same concentration range, clofazimine inhibited lymphocyte transformation. The inhibitory effect on neutrophil motility was associated with a spontaneous stimulation of oxidative metabolism and could be prevented by coincubation of dapsone with clofazimine. after ingestion of clofazimine responsiveness of lymphocytes to mitogens was decreased in normal volunteers and leprosy patients: neutrophil motility in normal individuals was likewise inhibited.

Full text

PDF
693

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson R., Gatner E. M. Changes in neutrophil motility accompanying dapsone and rifampicin therapy. Lepr Rev. 1981 Mar;52(1):19–22. doi: 10.5935/0305-7518.19810003. [DOI] [PubMed] [Google Scholar]
  2. Anderson R., Gatner E. M., Imkamp F. M., Kok S. H. In vivo effects of propranolol on some cellular and humoral immune functions in a group of patients with lepromatous leprosy. Lepr Rev. 1980 Jun;51(2):137–148. doi: 10.5935/0305-7518.19800012. [DOI] [PubMed] [Google Scholar]
  3. Anderson R., Gatner E. M., van Rensburg C. E., Grabow G., Imkamp F. M., Kok S. K., van Rensburg A. J. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1981 Apr;19(4):495–503. doi: 10.1128/aac.19.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anderson R., van Rensburg A. J. The in vitro effects of propranolol and atenolol on neutrophil motility and post-phagocytic metabolic activity. Immunology. 1979 May;37(1):15–24. [PMC free article] [PubMed] [Google Scholar]
  5. BARRY V. C., BELTON J. G., CONALTY M. L., DENNENY J. M., EDWARD D. W., O'SULLIVAN J. F., TWOMEY D., WINDER F. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957 May 18;179(4568):1013–1015. doi: 10.1038/1791013a0. [DOI] [PubMed] [Google Scholar]
  6. Brandt L., Svensson B. Stimulation of macrophage phagocytosis by clofazimine. Scand J Haematol. 1973;10(4):261–264. doi: 10.1111/j.1600-0609.1973.tb00070.x. [DOI] [PubMed] [Google Scholar]
  7. Bullock W. E., Jr, Ho M. F., Chen M. J. Quantitative and qualitative studies of the local cellular exudative response in leprosy. J Reticuloendothel Soc. 1974 Nov;16(5):259–268. [PubMed] [Google Scholar]
  8. Cline M. J. Drug potentiation of macrophage function. Infect Immun. 1970 Nov;2(5):601–605. doi: 10.1128/iai.2.5.601-605.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Imkamp F. M. A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663). Lepr Rev. 1968 Jul;39(3):119–125. doi: 10.5935/0305-7518.19680022. [DOI] [PubMed] [Google Scholar]
  10. McDougall A. C. Dapsone. Clin Exp Dermatol. 1979 Jun;4(2):139–142. doi: 10.1111/j.1365-2230.1979.tb01608.x. [DOI] [PubMed] [Google Scholar]
  11. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  12. Root R. K., Stossel T. P. Myeloperoxidase-mediated iodination by granulocytes. Intracellular site of operation and some regulating factors. J Clin Invest. 1974 May;53(5):1207–1215. doi: 10.1172/JCI107667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schulz E. J. Forty-four months' experience in the treatment of leprosy with clofazimine (Lamprene (Geigy)). Lepr Rev. 1971 Sep;42(3):178–187. doi: 10.5935/0305-7518.19710021. [DOI] [PubMed] [Google Scholar]
  14. Sher R., Anderson R., Glover A., Wadee A. A. Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum. Infect Immun. 1978 Sep;21(3):959–965. doi: 10.1128/iai.21.3.959-965.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Theron A., Anderson R., Grabow G., Meiring J. L. In vitro and in vivo stimulation of neutrophil migration and lymphocyte transformation by thiamine related to inhibition of the peroxidase/H2O2/halide system. Clin Exp Immunol. 1981 May;44(2):295–303. [PMC free article] [PubMed] [Google Scholar]
  16. Vischer W. A. The experimental properties of G 30 320 (B 663)--a new anti-leprotic agent. Lepr Rev. 1969 Apr;40(2):107–110. doi: 10.5935/0305-7518.19690021. [DOI] [PubMed] [Google Scholar]
  17. WOOD H. G., KATZ J., LANDAU B. R. ESTIMATION OF PATHWAYS OF CARBOHYDRATE METABOLISM. Biochem Z. 1963;338:809–847. [PubMed] [Google Scholar]
  18. Ward P. A., Goralnick S., Bullock W. E. Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med. 1976 Jun;87(6):1025–1032. [PubMed] [Google Scholar]
  19. Yawalkar S. J., Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev. 1979 Jun;50(2):135–144. doi: 10.5935/0305-7518.19790020. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES